Every one of those 1 sits in a single category, earnings. Ginkgo Bioworks is most often covered alongside Jason Kelly, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.2.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Ginkgo Bioworks
Every one of those 1 sits in a single category, earnings. Ginkgo Bioworks is most often covered alongside Jason Kelly, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.2. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. Ginkgo Bioworks appears in 1 tracked Finance story from February 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 91 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Ginkgo Bioworks. Shared-story counts are live from our verified record — not editorial picks.
Ginkgo Bioworks (NYSE: DNA) outperformed analyst expectations by $0.38 EPS in its latest quarterly report, signaling a potential shift in the company's financial trajectory. The results suggest that the synthetic biology leader's cost-cutting measures and platform scaling are beginning to deliver tangible bottom-line improvements.
Ginkgo Bioworks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.